Efficacy and safety of TiNO-coated stents versus drug-eluting coronary stents. Systematic literature review and meta-analysis.

Frederic C. Daoud, MD, MSc[a], Louis Létinier, MD, MSc[a], Nicholas Moore, MD, PhD[a], Pierre Coste, MD[b], Pasi P. Karjalainen, MD, PhD[c]

Short title: TiNO-coated stents *vs.* DES meta-analysis

Abstract word count: 248

Manuscript file word count: 5,396 including 1914 words in the body of the article and tables

Figures: 4

Tables: 3

Affiliations

[a] Univ. Bordeaux, INSERM, BPH, U1219, F-33000, Bordeaux, France

[b] Coronary Care Unit, Cardiologic Hospital, University of Bordeaux, Pessac, France

[c] Cardiac unit, Heart and Lung Center, Helsinki University Hospital and Helsinki University, Helsinki, Finland

Address for correspondence

Frederic C. Daoud, M.D., M.Sc.
orcid.org/0000-0002-0469-9723
Université de Bordeaux
Unité de Pharmacologie clinique
INSERM U1219 Bordeaux Population Health Center
Bâtiment 1A, 1er étage, Case 36
146 rue Léo Saignat
33076 Bordeaux Cedex, France
Tel. +33 (0)5 57 57 15 60, Fax +33 (0)5 57 57 46 71 06
E-mail: frederic.daoud-pineau@u-bordeaux.fr

Abstract

Background:

Randomized clinical trials (RCTs) comparing percutaneous coronary interventions (PCI) with titanium-nitride-oxide coated stents (TiNOS) versus drug-eluting stents (DES) in coronary artery disease (CAD) have been published.

Objectives:

To compare the efficacy and safety of PCI with TiNOS versus DES at 1 and 5-year follow-up, in all CAD including acute coronary syndrome (ACS).

Methods:

A prospective systematic literature review and meta-analysis of RCTs were conducted according to published methods (Cochrane, PRISMA, GRADE). Medline, Embase, Cochrane database, Web of Science were searched on March 08, 2018. Fixed-effects Mantel-Haenszel pooled risk ratios (RR), TiNOS over DES, with 95% confidence intervals (CI) were computed with sensitivity analysis.

Results:

Five RCTs were eligible with n = 1,855 TiNOS *vs.* n = 1,363 DES at 1-year and n = 783 *vs.* n = 771 at 5-year follow-up. One-year RRs in ACS patients: Major Adverse Cardiac Events (MACE) 0.93 [0.72, 1.20], recurrent myocardial infarction (MI) 0.42 [0.28, 0.63], probable or definite stent thrombosis (ST): 0.35 [0.20, 0.64]. Estimates were robust to sensitivity analysis. Certainty of evidence was high in MACE, moderate in MI and ST due to the limited number of cases. Data were insufficient to draw conclusions about stable CAD patients and 5-year outcomes.

Conclusions:

This meta-analysis showed in ACS patients, similar risk of MACE with TiNOS and DES, at 1-year follow-up, and suggested a lower risk of MI and ST with TiNOS than with DES. These two safety signals in MI and ST with the current use of DES require further investigations.

Keywords

TiNOS; titanium nitride oxide coated stent; DES; systematic literature review; meta-analysis

Background

Clinical evidence has led practice guidelines to establish percutaneous coronary interventions (PCI) with drug-eluting stents (DES) as the standard of care in all Coronary Artery Disease (CAD) including Acute Coronary Syndrome (ACS).[1-6] The trade-off is the prolongation of dual antiplatelet therapy (DAPT).[7,8]

The two main types of eluted drugs used so far have been rapamycin-analogs such as sirolimus, and paclitaxel. These drugs share the common purpose of mitigating post-stenting restenosis.[9-11] Titanium-nitride-oxide coated coronary stents (TiNOS), also designated "bioactive stents" (BAS) have a pharmacologically inactive, non-absorbable coating and one preclinical study has shown less neointimal hyperplasia with that coating than with bare-metal stents (BMS).[12,13,14]

Objectives

The systematic literature review (SLR) is the first to compare the efficacy and safety of TiNOS *vs.* DES in CAD. The question was specified using the PICOS framework[15]:

Patients presented CAD including ACS. **I**ntervention was PCI using TiNOS and the **C**omparator was PCI using DES. **O**utcomes were device-oriented Major Adverse Cardiac Events (device-oriented MACE), recurrent myocardial infarction (MI), stent thrombosis (ST), and all-cause mortality ("total death": TD) at 1-year and 5-year follow-up. **S**tudy methods were randomized controlled clinical trials (RCTs).

Methods

This SLR was designed and conducted according to methods described in the Cochrane Handbook with the use of "Grading of Recommendations Assessment, Development and

Evaluation" (GRADE), and is reported according to "Preferred Reporting Items for Systematic

Reviews and Meta-Analyses" (PRISMA).[16-18]

The protocol was developed prospectively and registered in PROSPERO (CRD42018090622).

Data recording and the meta-analysis were conducted in RevMan 5.3 (Review Manager Version

5.3 software. Copenhagen, Denmark: The Nordic Cochrane Centre, 2014). The certainty of

evidence according to GRADE was rated with GRADEpro GDT software 2020 on-line version,

(https://gradepro.org). Additional analyses and cross-checks were performed in STATA 16

(StataCorp LP, College Station, Tx, USA) using the metan and metaprop packages.

MEDLINE, EMBASE, the Cochrane Library, and Web of Science electronic databases, were

queried on March 08 2018 using their own search engines. The search terms were: *((bioactive*

OR (Titanium AND nitride AND oxide) OR TiNO OR TNO OR BAS) AND stent) AND (DES OR

(drug AND eluting AND stent)) AND (RCT OR ((randomized OR randomised) AND controlled

AND trial)). No exclusion filter was applied related to language, country, year, or any other

aspect. The websites of AHA, TCT, ESC, EuroPCR, and clinicaltrials.gov were also searched.

The queries were updated on July 22 2020 when all initially identified RCTs were published to

retrieve new evidence if any, from RCTs meeting the PICOS specifications of this SLR.

The downloaded record files were imported and pooled and sifted in EndNote X8 (Clarivate

Analytics, Philadelphia, PA, USA). When duplicates were identified, only one version was kept.

When several references concerned the same study, their information was pooled using the

citation of the most recent one. Full articles were reviewed for all references.

Two reviewers (FD and LL) performed separately and in parallel, all the following steps:

screened all references, classified them according to the review protocol's inclusion and

exclusion criteria, extracted the characteristics and relevant data of each RCT into RevMan 5.3

tables, rated the risk of bias of individual RCTs, assessed each outcome per GRADE.

Results were then reconciled and disagreements were resolved by consensus after discussion

with a third reviewer (NM). The similarity of the definitions of endpoints used across the RCTs

and the ability to pool results was discussed with one investigator (PK). The risk of bias of

individual RCTs was rated according to the criteria proposed by the Cochrane Collaboration with

operator blinding as a separate item and the certainty of pooled evidence for each outcome

variable was rated according to GRADE. Study publications were included if they met the

following criteria: First-hand clinical evidence with prospective inclusion; patients with CAD

treated with coronary PCI; implantation of either TiNOS or DES after random allocation; target

outcomes reported at 1-year and/or 5-year follow-up; outcomes reported as the number of

patients with an event or their rate along with the corresponding sample size.

References were ruled out if any of the above criteria were not met or if they did not report

IRB/ethics committee approval and patient informed consent.

The primary outcome was device-oriented MACE at 12-month follow-up and the secondary

outcomes were MI, probable or definite ST, and TD.

All definitions were those of the Academic Research Consortium (ARC) 2007.[19] Device-oriented

MACE was the composite of Cardiac death (CD), Myocardial Infarction (MI) not attributable to

a non-target vessel, repeat Target Lesion Revascularization (TLR) driven by recurrent

myocardial ischemia.[1] The secondary outcome variables were the same at 5-year follow-up. All

outcomes were analyzed with stratification on ACS and other CAD.

The two treatment arms were compared for each endpoint using the risk ratio (RR) defined as *((n*

patients with an event in TiNOS)/(n patients in TiNOS))/((n patients with an event in DES)/(n

patients in DES)). As a result, if the frequency of events was greater in TiNOS than in DES, then

the RR would be greater than 1 and conversely. The analysis was performed according to the

intention-to-treat (ITT) method where a patient presenting an event was counted in the treatment

arm he/she had been randomized to and where the denominator was the number of patients

randomized to the corresponding arm.

Individual study and pooled RR with 95% confidence interval (CI [,]) were calculated. Pooling

used the Mantel-Haenszel (M-H) fixed-effect model if no significant heterogeneity between the

RRs of individual RCTs was detected, and the M-H random-effects model otherwise.[16,20,21]

Results

The study identification and selection processes after the initial extraction were described in a

PRISMA flowchart (Figure 1). Overall, 111 references were identified and screening resulted in

8 publications and 1 presentation (the TIDES-ACS trial) with first-hand data concerning 5 RCTs,

all of which were included in the meta-analysis.

The number of patients at baseline and at 1-year follow-up was n = 2,951 with n = 1,855 in the

TiNOS arm and n = 1,363 in the DES arm. The number who had reached 5-year follow-up was n

= 783 (TiNOS) and n = 773 (DES). Two RCTs (TIDE and TITANIC-XV) combined patients

with ACS and other CAD without reporting outcomes separately for those two subgroups, while

the three others included patients with ACS only (TITAX-AMI, BASE-ACS, and TIDES-ACS).

The baseline characteristics are summarized in Table 1. Funnel plots and Harbord tests did not

detect a risk of publication bias.

The risk of bias in individual RCTs was low or moderate in all RCTs except for the operator's

knowledge of the type of stent during the intervention.

The pooled RRs of all outcomes at 1-year and 5-year follow-ups, in all CAD and the ACS

subgroup, along with sensitivity analysis are reported in Table 2. The number of studies and

events is insufficient to conclude about 5-year outcomes.

The stratified Forrest plots (ACS *vs.* other CAD) with heterogeneity analysis show no significant

difference in 1-year MACE between TiNOS and DES, but show significantly lower rates of

recurrent MI and ST with TiNOS compared to DES (Figure 2 to Figure 4). Effect size and

robustness to sensitivity analysis in recurrent MI and ST found in all CAD are driven by the

results in the ACS subgroup.

Stratified analysis showed a relatively low number of patients with "other CAD" stratum

compared to the ACS (14.8% versus 85.2% among 3,218 patients, Figure 2) and significant

heterogeneity between the strata (p = 0.05, I^2 = 73.4%, Figure 2). This leads reviewers to narrow

down the scope of the subsequent steps of this SLR to 1-year outcomes in ACS only.

Results in ACS at 1-year follow-up

The pooled RR of MACE is non-significant 0.93 [0.72, 1.20], without significant heterogeneity

between studies (I^2 = 0%) (Figure 2) and is robust to sensitivity analysis (Table 2). The Optimal

Information Size (OIS) criterion is met, the number of cases that would need to be shifted from

the DES arm to the TiNOS arm in a simulation is close to 2.7 times the non-inferiority margin,

and no publication bias is detected. The certainty of the evidence according to GRADE is

therefore rated high (Table 3).

The pooled RR of recurrent MI is significant 0.33 [0.22, 0.51] without significant heterogeneity

(I^2 = 0%) (Figure 3), is robust to sensitivity analysis. However, given the OIS criterion is not met

and the number of events is well below the n = 300 rule of thumb, this RR presents

imprecision/fragility. Considering no publication bias is detected, the certainty of the evidence

according to GRADE is rated moderate.

The pooled RR of ST in ACS at 1-year follow-up is significant 0.35 [0.20, 0.64] without

significant heterogeneity ($I^2 = 0\%$) (Figure 4), is robust to sensitivity analysis. Given the OIS

criterion is not met and the number of events is well below the n = 300 rule of thumb, this RR

presents imprecision/fragility. Considering no publication bias is detected, the certainty of the

evidence is rated moderate.

The pooled RR of TD in ACS at 1-year follow-up is not significant 0.78 [0.47, 1.27], with

significant heterogeneity between RCTs ($I^2 = 66\%$), presents imprecision/fragility due to

insufficient amount of information (the OIS criterion is not met and the number of events being

well below the n = 300 rule of thumb), and a lack of robustness to sensitivity analysis.

Considering no publication bias is detected, the certainty of the evidence is rated low.

Discussion

The strengths of this SLR are the low risk of publication bias and the robustness of the sensitivity

analysis of all outcomes at 1- year except for TD. Given the certainty of evidence per GRADE,

the results are considered valid.

The main weaknesses are the low number of studies and patients, especially in CAD other than

ACS, and at 5-year follow-up. Additional 5-year data will be pooled when TIDE-ACS final

results are published. Another relative weakness is the pooling of different generations of TiNOS

and DES in ACS, especially paclitaxel-eluting stainless steel stents with everolimus-eluting

stents with cobalt-chromium or platinum-chromium platforms. Indeed, the 3 ACS RCTs show no

or minor-only heterogeneity (i.e. 95% CIs overlap or their edges touch) among the DES groups

and the TiNOS groups, respectively, in terms of 1-year incidence rates of MACE, recurrent MI,

and ST. Published RCTs so far comparing paclitaxel-DES and other DES have not shown

significant differences in STEMI or NSTEMI, whereas paclitaxel-DES have been demonstrated

to be inferior in other indications than ACS.

Conclusions

This systematic literature review shows that titanium-nitride oxide coated-coronary stents and

drug-eluting stents have a similar risk of major adverse cardiac events at one 1-year follow-up

when used in acute coronary syndrome. This result is robust and the level of certainty of this

conclusion is high.

It also suggests a lower risk of recurrent myocardial infarction and stent thrombosis with

titanium-nitride oxide coated-coronary stents than with drug-eluting stents. The size of the

pooled risk ratios and the robustness to sensitivity analysis are safety signals concerning the use

of drug-eluting stents when compared to titanium-nitride oxide coated-coronary stents in acute

coronary syndrome. This requires further investigation.

The evidence is insufficient to conclude about outcomes at five-year follow-up and in patients

with chronic coronary artery syndromes.

Supplemental material:

- Details of methods applied in this SLR.

- Methods of individual RCTs

- Table of the number of patients with events – ITT

- Funnel plots and results of Harbord tests.

- Summary of risk of bias in individual RCTs

- Pooled results of TD

- Notes of GRADE analysis

- Heterogeneity analysis of event incidence rates among DES and TiNOS arms.

- PRISMA checklist

Figure 1 PRISMA flowchart

Figure 2 MACE at 1-year – pooled and stratified

240 **Figure 3 MI at 1-year – pooled and stratified**

Figure 4 ST at 1-year – pooled and stratified

 Table 1 Baseline characteristics

Study	Age & prior events			Clinical presentation			Procedural data & medication			Attrition & cross-overs
Stent		TiNOS	DES		TiNOS	DES		TiNOS	DES	
TITAX-AMI[22,23] [NCT00495664]	Patients n age prior MI prior PCI prior CABG	214 64±11 15% 10% 7%	211 64±11 9% 5% 6%	NSTEMI STEMI	61% 39%	54% 46%	stents in culprit lesion n TSL (mm) post-dilation procedural success DAPT 12-months	1.1±0.3 18.5±6.4 42% 99.5% 31%	1.1±0.4 19.2±7.2 35% 98.1% 65%	LFU 1y TiNOS: 0 DES: 0 5y TiNOS 3 DES: 7
TIDE[24] [NCT00492908]	Patients n age prior MI prior PCI prior CABG	152 65.9±9.0 27.6% 25.7% 7.9%	150 63.4±10.5 28.7% 21.3% 25.3% 2.7%	Stable CAD NSTEMI Unstable angina	57.9% 32.9% 9.2%	47.3% 42.0% 10.7%	stents in culprit lesion n TSL (mm) device success DAPT 12-months	1.28±0.55 19.3±11.1 93.0%	1.17±0.45 19.6±10.0 94.6%	LFU 1y TiNOS: 0 DES: 2 5y : N.R.
TITANIC-XV[25] [NCT01510509]	Patients n age prior MI prior PCI prior CABG	83 66.5±8.8 10.8% 8.4% 2.4%	90 64.5±10.1 15.6% 11.1% 2.2%	NST ACS Deducted other CAD	69.9% 30.1%	60.0% 40.0%	stents in culprit lesion n TSL (mm) stent failure DAPT 12 months	1.1±0.3 18.72±8.20 N.R.	1.1±0.3 21.63±9.65 N.R.	N.R.
BASE-ACS[26,27] [NCT00819923]	patients age prior MI prior PCI prior CABG	417 63±12 13.4% 9.6% 4.8%	410 63±12 9.8% 10.5% 4.1%	NSTEMI STEMI Unstable angina	49.4% 38.8% 11.8%	45.6% 38.8% 15.6%	stents in culprit lesion n TSL (mm) post-dilation stent failure DAPT : Aspirin : protocol indefinite, actual N.R. Clopidogrel: protocol 6 months, actual N.R.	1.15±0.38 20.8±9.4 42.2% 0.0%	1.14±0.36 20.6±8.2 43.9% 1.0%	LFU 1y TiNOS: 3 DES: 3 5y TiNOS 29 DES: 28
TIDES-ACS[28,29] [NCT02049229]	Patients n age prior MI prior PCI prior CABG	989 62.7±10. 7.6% 7.0% 0.6%	502 62.6±10.5 9.0% 6.6% 1.2%	NSTEMI STEMI	46.3% 44.9%	45.0% 47.6%	stents in culprit lesion n TSL (mm) post-dilation stent failure DAPT 12-months	1.13±0.38 20.5±7.8 33.0% 0.3% 80.3%	1.14±0.37 20.6±7.2 38.0% 1.0% 86.0%	LFU 1y TiNOS: 7 DES: 4

Table 2 Detailed pooled results with sensitivity analysis

M-H fixed-effects RR & 95% CI	Pooled RR with all RCTs		Sensitivity analysis: Pooled RR recalculated after removing the following RCT:				
Endpoint	Sub-group stratification	No subgroup stratification	TITAX-AMI	TIDE	TITANIC-XV	BASE-ACS	TIDES-ACS
All, MACE 1-y	1.05 [0.84, 1.31]	1.05 [0.84, 1.31]	1.11 [0.87, 1.42]	1.01 [0.79, 1.29]	0.98 [0.78, 1.24]	1.04 [0.80, 1.35]	1.13 [0.86, 1.47]
All, MACE 5-y		0.82 [0.66, 1.02]	0.91 [0.70, 1.19]	0.74 [0.58, 0.95](**)	N.A.	0.83 [0.62, 1.10]	N.A.
All, ST 1-y	0.39 [0.22, 0.69]	0.39 [0.22, 0.69]	0.46 [0.25, 0.84]	0.35 [0.20, 0.64]	0.39 [0.22, 0.69]	0.36 [0.18, 0.72]	0.38 [0.16, 0.87]
All, ST 5-y		0.25 [0.11, 0.55]	0.37 [0.14, 0.99]	0.20 [0.09, 0.49]	N.A.	0.22 [0.07, 0.70]	N.A.
All, MI 1-y	0.39 [0.27, 0.57]	0.39 [0.27, 0.57]	0.36 [0.23, 0.56]	0.34 [0.22, 0.52]	0.39 [0.26, 0.57]	0.40 [0.26, 0.63]	0.50 [0.32, 0.79]
All, MI 5-y		0.54 [0.38, 0.76]	0.59 [0.38, 0.93]	0.51 [0.35, 0.74]	N.A.	0.56 [0.33, 0.94]	N.A.
All, TD 1-y	0.78 [0.48, 1.27]	0.78 [0.48, 1.27]	0.77 [0.46, 1.32]	0.78 [0.47, 1.27]	0.78 [0.48, 1.27]	0.49 [0.26, 0.95](*)	1.22 [0.65, 2.28]
All, TD 5-y		1.03 [0.74, 1.45]	1.14 [0.75, 1.73]	0.95 [0.65, 1.37]	N.A.	1.05 [0.65, 1.69]	N.A.
ACS, MACE 1-y	0.93 [0.72 1.20]	0.93 [0.72, 1.20]	0.97 [0.73, 1.30]	N.A.	N.A.	0.86 [0.63, 1.19]	0.95 [0.68, 1.33]
ACS, MACE 5-y		0.74 [0.58, 0.95]	0.81 [0.59, 1.12](**)	N.A.	N.A.	0.65 [0.44, 0.95](**)	N.A.
ACS, ST 1-y	0.35 [0.20, 0.64]	0.35 [0.20, 0.64]	0.42 [0.22, 0.78]	N.A.	N.A.	0.32 [0.15, 0.65]	0.31 [0.12, 0.77]
ACS, ST 5-y		0.20 [0.09, 0.49]	0.28 [0.09, 0.85](**)	N.A.	N.A.	0.28 [0.09, 0.85](**)	N.A.
ACS, MI 1-y	0.33 [0.22, 0.51]	0.42 [0.28, 0.63]	0.38 [0.24, 0.62]	N.A.	N.A.	0.44 [0.27, 0.71]	0.43 [0.25, 0.74]
ACS, MI 5-y		0.51 [0.35, 0.74]	0.56 [0.33, 0.94](**)	N.A.	N.A.	0.47 [0.28, 0.79](**)	N.A.
ACS, TD 1-y	0.78 [0.47, 1.27]	0.78 [0.47, 1.27]	0.77 [0.45, 1.32]	N.A.	N.A.	0.47 [0.24, 0.93](*)	1.23 [0.64, 2.35]
ACS, TD 5-y		0.95 [0.65, 1.37]	1.02 [0.63, 1.65](**)	N.A.	N.A.	0.85 [0.48, 1.53](**)	N.A.

253 Notes: (*) borderline shift with 3 or fewer RCTs, (**)single-trial left   N.A. Not applicable.

Table 3 GRADE profile

Outcome	Risk of bias	Inconsistency	Indirectness	Imprecision	Publication bias	Overall certainty of evidence
MACE 1-year ACS	not serious [a]	not serious [b]	not serious [c]	not serious [d]	none detected	⊕⊕⊕⊕ HIGH
MI 1-year ACS	not serious [a]	not serious [e]	not serious [f]	serious [g]	none detected	⊕⊕⊕⊖ MODERATE
ST 1-year ACS	not serious [a]	not serious [h]	not serious [i]	serious [j]	none detected	⊕⊕⊕⊖ MODERATE
TD 1-year ACS	not serious [a]	serious [k]	not serious [l]	serious [m]	none detected	⊕⊖⊕⊖ LOW

Funding

This work was exclusively funded by the University of Bordeaux and INSERM BPH U1219

Disclosures

Frederic Daoud: Biostatistical consulting for several companies including Svelte Medical,
Robocath, and Carmat.

Louis Létinier: No disclosure.

Nicholas Moore: No disclosure.

Pierre Coste: No disclosure.

Pasi Karjalainen: No disclosure.

References

1. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis
SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID,
Mukherjee D, Ting H, O'Gara PT, Kushner FG, Ascheim DD, Brindis RG, Casey Jr DE 1 ,
Chung MK, de Lemos JA, Diercks DB, Fang JC, Franklin BA, Granger CB, Krumholz HM,
Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE,
Tommaso CL, Tracy CM, Woo YJ, Zhao DX. 2011 ACCF/AHA/SCAI Guideline for
Percutaneous Coronary Intervention: a report of the American College of Cardiology
Foundation/American Heart Association Task Force on Practice Guidelines and the Society for
Cardiovascular Angiography and Interventions. Circulation. 2011 Dec 6; 124(23):e574-651. doi:
10.1161/CIR.0b013e31823ba622. Epub 2011 Nov 7. Erratum in: Circulation. 2012 Feb
28;125(8):e412. Dosage error in article text. PMID: 22064601.

2. O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM,
Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA,
Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo
YJ, Zhao DX, Anderson JL, Jacobs AK, Halperin JL, Albert NM, Brindis RG, Creager MA,
DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Kushner FG, Ohman EM, Stevenson WG,
Yancy CW; American College of Cardiology Foundation/American Heart Association Task
Force on Practice Guidelines.. 2013 ACCF/AHA guideline for the management of ST-elevation
myocardial infarction: a report of the American College of Cardiology Foundation/American
Heart Association Task Force on Practice Guidelines. Circulation. 2013 Jan 29; 127(4):e362-
425. doi: 10.1161/CIR.0b013e3182742cf6. Epub 2012 Dec 17. Erratum in: Circulation. 2013
Dec 24;128(25):e481. PMID: 23247304.

3. Task Force Members, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj
A, Bugiardini R, Crea F, Cuisset T, Di Mario C, Ferreira JR, Gersh BJ, Gitt AK, Hulot JS, Marx
N, Opie LH, Pfisterer M, Prescott E, Ruschitzka F, Sabaté M, Senior R, Taggart DP, van der
Wall EE, Vrints CJ; ESC Committee for Practice Guidelines, Zamorano JL, Achenbach S,
Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D,
Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli
MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S;
Document Reviewers, Knuuti J, Valgimigli M, Bueno H, Claeys MJ, Donner-Banzhoff N, Erol
C, Frank H, Funck-Brentano C, Gaemperli O, Gonzalez-Juanatey JR, Hamilos M, Hasdai D,
Husted S, James SK, Kervinen K, Kolh P, Kristensen SD, Lancellotti P, Maggioni AP, Piepoli
MF, Pries AR, Romeo F, Rydén L, Simoons ML, Sirnes PA, Steg PG, Timmis A, Wijns W,
Windecker S, Yildirir A, Zamorano JL. 2013 ESC guidelines on the management of stable
coronary artery disease: the Task Force on the management of stable coronary artery disease of
the European Society of Cardiology. Eur Heart J. 2013; 34(38):2949–3003. doi:
10.1093/eurheartj/eht296. Epub 2013 Aug 30. Erratum in: Eur Heart J. 2014 Sep 1;35(33):2260-
1. PMID: 23996286.

4. Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, Jaffe AS,
Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine
MS, Smalling RW, Zieman SJ; ACC/AHA Task Force Members; Society for Cardiovascular
Angiography and Interventions and the Society of Thoracic Surgeons. 2014 AHA/ACC guideline
for the management of patients with non-ST-elevation acute coronary syndromes: a report of the
American College of Cardiology/American Heart Association Task Force on Practice
Guidelines. Circulation. 2014; 130(25):2354-2394. doi: 10.1161/CIR.0000000000000133. Epub
2014 Sep 23. Erratum in: Circulation. 2014 Dec 23;130(25):e431-2. Dosage error in article text.
PMID: 25249586.

5. Collet J, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt D, Dendale P, Dorobantu M,
Edvardsen T, Folliguet T, Gale C, Gilard M, Jobs A, Jüni P, Lambrinou E, Lewis B, Mehilli J,
Meliga E, Merkely B, Mueller C, Roffi M, Rutten F, Sibbing D, Siontis G, ESC Scientific
Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in
patients presenting without persistent ST-segment elevation. Eur Heart J. 2020 Aug 29; ehaa575.
doi: 10.1093/eurheartj/ehaa575. Epub ahead of print. PMID: 32860058.

6. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP,
Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M,
Valgimigli M, Varenhorst C, Vranckx P, Widimský P; ESC Scientific Document Group. 2017
ESC Guidelines for the management of acute myocardial infarction in patients presenting with
ST-segment elevation: The Task Force for the management of acute myocardial infarction in
patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur
Heart J. 2018; 39(2):119-177. doi: 10.1093/eurheartj/ehx393. PMID: 28886621.

7. Costa F, Van Klaveren D, Feres F, James S, Räber L, Pilgrim T, Hong MK, Kim HS,
Colombo A, Steg PG, Bhatt DL, Stone GW, Windecker S, Steyerberg EW, Valgimigli M;
PRECISE-DAPT Study Investigators. Dual Antiplatelet Therapy Duration Based on Ischemic
and Bleeding Risks After Coronary Stenting. J Am Coll Cardiol. 2019; 73(7):741-754. doi:
10.1016/j.jacc.2018.11.048. PMID: 30784667.

8. Saito Y, Kobayashi Y. Update on Antithrombotic Therapy after Percutaneous Coronary
Intervention Intern Med. 2020; 59(3):311-321. doi: 10.2169/internalmedicine.3685-19. Epub
2019 Oct 7. PMID: 31588089; PMCID: PMC7028427.

9. Wessely R, Schömig A, Kastrati A. Sirolimus and Paclitaxel on polymer-based drug-eluting
stents: similar but different. J Am Coll Cardiol. 2006; 47(4):708-714. doi:
10.1016/j.jacc.2005.09.047. Epub 2006 Jan 26. PMID: 16487832.

10. Patterson C, Mapera S, Li HH, Madamanchi N, Hilliard E, Lineberger R, Herrmann R,
Charles P. Comparative effects of paclitaxel and rapamycin on smooth muscle migration and
survival: role of AKT-dependent signaling. Arterioscler Thromb Vasc Biol. 2006; 26(7):1473-
1480. doi: 10.1161/01.ATV.0000223866.42883.3b. Epub 2006 Apr 27. PMID: 16645158.

11. Yazdani SK, Sheehy A, Pacetti S, Rittlemeyer B, Kolodgie FD, Virmani R. Stent Coating
Integrity of Durable and Biodegradable Coated Drug Eluting Stents. J Interv Cardiol. 2016;
29(5):483-490. doi: 10.1111/joic.12303. Epub 2016 Jun 10. PMID: 27282892.

12. Windecker S, Mayer I, De Pasquale G, Maier W, Dirsch O, De Groot P, Wu YP, Noll G,
Leskosek B, Meier B, Hess OM; Working Group on Novel Surface Coating of Biomedical
Devices (SCOL). Stent coating with titanium-nitride-oxide for reduction of neointimal
hyperplasia. Circulation. 2001; 104(8):928-933. doi: 10.1161/hc3401.093146. PMID: 11514381.

13. Ignarro LJ, Buga GM, Wei LH, Bauer PM, Wu G, del Soldato P. Role of the arginine-nitric
oxide pathway in the regulation of vascular smooth muscle cell proliferation. Proc Natl Acad Sci
U S A. 2001; 98(7):4202-4208. doi: 10.1073/pnas.071054698. Epub 2001 Mar 20. PMID:
11259671; PMCID: PMC31203.

14. Windecker S, Simon R, Lins M, Klauss V, Eberli FR, Roffi M, Pedrazzini G, Moccetti T,
Wenaweser P, Togni M, Tüller D, Zbinden R, Seiler C, Mehilli J, Kastrati A, Meier B, Hess OM.
Randomized comparison of a titanium-nitride-oxide-coated stent with a stainless steel stent for
coronary revascularization: the TiNOX trial. Circulation. 2005; 111(20):2617-2622. doi:
10.1161/CIRCULATIONAHA.104.486647. Epub 2005 May 9. PMID: 15883209.

15. Huang X, Lin J, Demner-Fushman D. Evaluation of PICO as a knowledge representation for
clinical questions. AMIA Annu Symp Proc. 2006; 2006:359-363. PMID: 17238363; PMCID:
PMC1839740.

16. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions.
www.cochrane-handbook.org, version 5.1.0 updated March 2011.

17. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M,
Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews
and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.
BMJ. 2009; 339:b2700. doi: 10.1136/bmj.b2700. PMID: 19622552; PMCID: PMC2714672.

18. Schünemann H, Brożek J, Guyatt G, Oxman A, editors. GRADE handbook for grading
quality of evidence and strength of recommendations. Updated October 2013. The GRADE
Working Group, 2013. Available from guidelinedevelopment.org/handbook.

19. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA,
Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW; Academic
Research Consortium. Clinical end points in coronary stent trials: a case for standardized
definitions. Circulation. 2007; 115(17):2344-2351. doi:
10.1161/CIRCULATIONAHA.106.685313. PMID: 17470709.

20. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-
88. doi: 10.1016/0197-2456(86)90046-2. PMID: 3802833.

21. Borenstein M, Hedges LV, Higgins JP, Rothstein HR. A basic introduction to fixed-effect
and random-effects models for meta-analysis. Res Synth Methods. 2010; 1(2):97-111. doi:
10.1002/jrsm.12. Epub 2010 Nov 21. PMID: 26061376.

22. Karjalainen PP, Ylitalo A, Niemelä M, Kervinen K, Mäkikallio T, Pietili M, Sia J,
Tuomainen P, Nyman K, Airaksinen KE. Titanium-nitride-oxide coated stents versus paclitaxel-
eluting stents in acute myocardial infarction: a 12-months follow-up report from the TITAX
AMI trial. EuroIntervention. 2008; 4(2):234-241. doi: 10.4244/eijv4i2a42. PMID: 19110789.

23. Tuomainen PO, Ylitalo A, Niemelä M, Kervinen K, Pietilä M, Sia J, Nyman K, Nammas W,
Airaksinen KE, Karjalainen PP. Five-year clinical outcome of titanium-nitride-oxide-coated
bioactive stents versus paclitaxel-eluting stents in patients with acute myocardial infarction:
long-term follow-up from the TITAX AMI trial. Int J Cardiol. 2013; 168(2):1214-1219. doi:
10.1016/j.ijcard.2012.11.060. Epub 2012 Dec 3. PMID: 23218575.

24. Pilgrim T, Räber L, Limacher A, Löffel L, Wenaweser P, Cook S, Stauffer JC, Togni M,
Vogel R, Garachemani A, Moschovitis A, Khattab AA, Seiler C, Meier B, Jüni P, Windecker S.
Comparison of titanium-nitride-oxide-coated stents with zotarolimus-eluting stents for coronary
revascularization a randomized controlled trial. JACC Cardiovasc Interv. 2011; 4(6):672-682.
doi: 10.1016/j.jcin.2011.02.017. PMID: 21700254.

25. López-Mínguez JR, Nogales-Asensio JM, Doncel-Vecino LJ, Merchán-Herrera A, Pomar-
Domingo F, Martínez-Romero P, Fernández-Díaz JA, Valdesuso-Aguilar R, Moreu-Burgos J,
Díaz-Fernández J; members of the TITANIC XV Working Group. A randomized study to
compare bioactive titanium stents and everolimus-eluting stents in diabetic patients (TITANIC
XV): 1-year results. Rev Esp Cardiol (Engl Ed). 2014; 67(7):522-530. doi:
10.1016/j.rec.2013.10.021. Epub 2014 Apr 3. PMID: 24952391.

26. Karjalainen PP, Nammas W, Ylitalo A, de Bruyne B, Lalmand J, de Belder A, Rivero-Crespo
F, Kervinen K, Airaksinen JKE. Long-term clinical outcome of titanium-nitride-oxide-coated
stents versus everolimus-eluting stents in acute coronary syndrome: Final report of the BASE
ACS trial. Int J Cardiol. 2016; 222:275-280. doi: 10.1016/j.ijcard.2016.07.267. Epub 2016 Aug
1. PMID: 27497110.

27. Karjalainen PP, Niemelä M, Airaksinen JK, Rivero-Crespo F, Romppanen H, Sia J, Lalmand
J, de Bruyne B, Debelder A, Carlier M, Nammas W, Ylitalo A, Hess OM; BACE-ACS study
investigators. A prospective randomised comparison of titanium-nitride-oxide-coated bioactive
stents with everolimus-eluting stents in acute coronary syndrome: the BASE-ACS trial.
EuroIntervention. 2012; 8(3):306-315. doi: 10.4244/EIJV8I3A49. PMID: 22829506.

28. Colkesen EB, Eefting FD, Rensing BJ, Suttorp MJ, Ten Berg JM, Karjalainen PP, Van Der
Heyden JA. TIDES-ACS Trial: comparison of titanium-nitride-oxide coated bio-active-stent to

the drug (everolimus)-eluting stent in acute coronary syndrome. Study design and objectives.
Minerva Cardioangiol. 2015; 63(1):21-29. PMID: 25670057.

29. Tonino PAL, Pijls NHJ, Collet C, Nammas W, Van der Heyden J, Romppanen H, Kervinen
K, Airaksinen JKE, Sia J, Lalmand J, Frambach P, Penaranda AS, De Bruyne B, Karjalainen PP;
TIDES-ACS Study Group. Titanium-Nitride-Oxide-Coated Versus Everolimus-Eluting Stents in
Acute Coronary Syndrome: The Randomized TIDES-ACS Trial. JACC Cardiovasc Interv. 2020;
13(14):1697-1705. doi: 10.1016/j.jcin.2020.04.021. PMID: 32703593.

30. Savović J, Weeks L, Sterne JA, Turner L, Altman DG, Moher D, Higgins JP. Evaluation of
the Cochrane Collaboration's tool for assessing the risk of bias in randomized trials: focus
groups, online survey, proposed recommendations and their implementation. Syst Rev. 2014;
3:37. doi: 10.1186/2046-4053-3-37. PMID: 24731537; PMCID: PMC4022341.

31. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ;
GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and
strength of recommendations. BMJ. 2008; 336(7650):924-926. doi:
10.1136/bmj.39489.470347.AD. PMID: 18436948; PMCID: PMC2335261.

32. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, Devereaux PJ,
Montori VM, Freyschuss B, Vist G, Jaeschke R, Williams JW Jr, Murad MH, Sinclair D, Falck-
Ytter Y, Meerpohl J, Whittington C, Thorlund K, Andrews J, Schünemann HJ. GRADE
guidelines 6. Rating the quality of evidence--imprecision. J Clin Epidemiol. 2011; 64(12):1283-
1293. doi: 10.1016/j.jclinepi.2011.01.012. Epub 2011 Aug 11. PMID: 21839614.

33. GRADEpro GDT: GRADEpro Guideline Development Tool [Software]. McMaster
University, 2015 (developed by Evidence Prime, Inc.). Available from https://gdt.gradepro.org

34. Pogue JM, Yusuf S. Cumulating evidence from randomized trials: utilizing sequential
monitoring boundaries for cumulative meta-analysis. Control Clin Trials. 1997; 18(6):580-593;
discussion 661-6. doi: 10.1016/s0197-2456(97)00051-2. PMID: 9408720.

35. Seeger P, Gabrielsson A. Applicability of the Cochran Q test and the F test for statistical
analysis of dichotomous data for dependent samples. Psychol Bull. 1968; 69(4):269-277. doi:
10.1037/h0025667. PMID: 5659656.

36. Gavaghan DJ, Moore RA, McQuay HJ. An evaluation of homogeneity tests in meta-analyses
in pain using simulations of individual patient data. Pain. 2000; 85(3):415-424. doi:
10.1016/s0304-3959(99)00302-4. PMID: 10781914.

37. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;
21(11):1539-1558. doi: 10.1002/sim.1186. PMID: 12111919.

38. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-
analyses. BMJ. 2003; 327(7414):557-560. doi: 10.1136/bmj.327.7414.557. PMID: 12958120;
PMCID: PMC192859.

39. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a
simple, graphical test. BMJ. 1997; 315(7109):629-634. doi: 10.1136/bmj.315.7109.629. PMID:
9310563; PMCID: PMC2127453.

40. Egger M, Smith GD. Bias in location and selection of studies. BMJ. 1998; 316(7124):61-66.
doi: 10.1136/bmj.316.7124.61. PMID: 9451274; PMCID: PMC2665334.

41. Sterne JAC, Egger M, Davey Smith G. Investigating and dealing with publication and other
biases. In: Egger M, Davey Smith G, Altman DG (eds). Systematic Reviews in Health Care:
Meta-Analysis in Context. London: BMJ Publishing Group, 2001:189-208.

42. Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-analyses
of controlled trials with binary endpoints. Stat Med. 2006; 25(20):3443-3457. doi:
10.1002/sim.2380. PMID: 16345038.